Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10315508" target="_blank" >RIV/00216208:11110/15:10315508 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10315508

Výsledek na webu

<a href="http://dx.doi.org/10.1517/14740338.2015.1039980" target="_blank" >http://dx.doi.org/10.1517/14740338.2015.1039980</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1517/14740338.2015.1039980" target="_blank" >10.1517/14740338.2015.1039980</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Popis výsledku v původním jazyce

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of theEuropean Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excludingother side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of thi

Název v anglickém jazyce

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Popis výsledku anglicky

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of theEuropean Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excludingother side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of thi

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Opinion on Drug Safety

ISSN

1474-0338

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

21

Strana od-do

935-955

Kód UT WoS článku

000354541400012

EID výsledku v databázi Scopus

2-s2.0-84929578095